Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of "Hold" by Analysts

Key Points

• Recursion Pharmaceuticals, Inc. has received a consensus recommendation of "Hold" from six research firms, with an average price target of $7.00 per share.
• The company reported a loss of $0.41 earnings per share (EPS) for the last quarter, missing analysts' expectations, but achieved revenue of $19.10 million, which was higher than projected.
• Institutional investors collectively own 89.06% of Recursion Pharmaceuticals' stock, reflecting significant interest from large investment firms.

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been given a consensus recommendation of "Hold" by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.00.

Several analysts have recently commented on the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective for the company.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RXRX. TD Waterhouse Canada Inc. lifted its stake in shares of Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company's stock worth $29,000 after acquiring an additional 2,200 shares in the last quarter. AlphaQuest LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter valued at approximately $36,000. GAMMA Investing LLC raised its stake in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares in the last quarter. NewEdge Advisors LLC raised its stake in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded up $0.13 during midday trading on Wednesday, hitting $5.77. The company had a trading volume of 14,820,853 shares, compared to its average volume of 26,871,796. The company's 50 day simple moving average is $5.49 and its 200 day simple moving average is $5.83. Recursion Pharmaceuticals has a 52-week low of $3.79 and a 52-week high of $12.36. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -3.24 and a beta of 0.93. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million during the quarter, compared to analysts' expectations of $15.38 million. During the same quarter last year, the business posted ($0.40) earnings per share. The company's revenue for the quarter was up 33.3% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.